Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Clin Apher ; 36(4): 612-620, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-33964038

RESUMO

BACKGROUND: This study assessed pharmacoeconomic costs associated with extracorporeal photopheresis (ECP) compared with other available second-line therapies for chronic graft-vs-host disease (cGvHD) in a tertiary Spanish institution. METHODS: Patients (≥18 years) diagnosed with steroid-refractory cGvHD were eligible. Data were collected retrospectively from index date until 1 year or relapse. Patients were distributed in two cohorts (ECP vs non-ECP), matched by age (≤ or > 40), hematopoietic stem cell transplant (HLA-identical sibling donor or other) and number of previous immunosuppressive lines (1, 2, or ≥ 3). Costs were assigned using the 2016 diagnosis-related group (DRG) system: DRG 579 (€22 383) overnight stay due to major complication (ie, sepsis, pneumonia, parenteral nutrition, or respiratory failure), and DRG 875 (€5154) if no major complication. The primary endpoint was healthcare resource utilization per patient. RESULTS: Forty patients (n = 20 per cohort) were included. Median age was 49, and 37.5% were female. Mean total cost per patient was €25 319 (95% CI: €17 049-€33 590) across the two cohorts, with a slightly lower mean cost per ECP-treated patient (€23 120) compared with the non-ECP cohort (€27 519; P = .597). Twenty-seven inpatient hospitalizations occurred among ECP-treated patients, vs 33 in the non-ECP cohort. Day hospital and external consultations were more frequent in the ECP cohort. However, fewer inpatient admissions included DRG 579 compared with the non-ECP cohort (44% vs 58%). Inpatient length of stay was slightly shorter in the ECP cohort (30 vs 49 days; P = .298). CONCLUSIONS: ECP treatment may yield economic savings in Spain through resource savings and moving costs toward outpatient care.


Assuntos
Doença Enxerto-Hospedeiro/tratamento farmacológico , Hospitais , Fotoferese/economia , Fotoferese/métodos , Esteroides/uso terapêutico , Adulto , Idoso , Doença Crônica , Farmacoeconomia , Feminino , Doença Enxerto-Hospedeiro/economia , Transplante de Células-Tronco Hematopoéticas/métodos , Hospitalização , Humanos , Imunossupressores , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Pacientes Ambulatoriais , Estudos Retrospectivos , Risco , Espanha/epidemiologia , Resultado do Tratamento , Adulto Jovem
2.
Transpl Infect Dis ; 22(4): e13301, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32363665

RESUMO

BACKGROUND: Enterovirus/rhinoviruses (EvRh) are the most common cause of respiratory virus infections in recipients of allogeneic stem cell transplantation (allo-HSCT). OBJECTIVE: We sought to analyze the value of the immunodeficiency scoring index (ISI) in predicting lower respiratory tract disease (LRTD) progression and mortality in a prospective cohort of consecutive adult (>16 years) allo-HSCT recipients with EvRh infection from December 1 2013 to December 1 2019 at two Spanish transplant centers. RESULTS: We included 234 allo-HSCT recipients with 383 EvRh episodes. Out of 383 EvRh episodes, 98 (25%) had LRTD. Multivariate logistic regression analysis identified three independent factors associated with LRTD progression: Ig G < 400 mg/dL, community-acquired respiratory virus (CARV) co-infection and high-risk ISI. Inclusion of Ig G levels and CARV co-infection in the ISI improved its performance by significantly increasing the area under the receiver operator characteristic curve (AUROC) from 0.643 to 0.734 (P = .03). Likewise, the two conditions identified by multivariate analyses as associated with higher probability of mortality were high-risk ISI and EvRh infection within 6 months after transplant. CONCLUSIONS: Our findings confirm the value of high-risk ISI in predicting both probability of EvRh LRTD and 3-month overall mortality. We also demonstrate that the original ISI could be adapted to other CARV types by including additional variables to improve its performance.


Assuntos
Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Síndromes de Imunodeficiência/virologia , Infecções por Picornaviridae/imunologia , Infecções Respiratórias/imunologia , Adolescente , Adulto , Idoso , Feminino , Humanos , Síndromes de Imunodeficiência/epidemiologia , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Infecções por Picornaviridae/mortalidade , Estudos Prospectivos , Curva ROC , Infecções Respiratórias/mortalidade , Infecções Respiratórias/virologia , Estudos Retrospectivos , Rhinovirus/imunologia , Espanha/epidemiologia , Transplante Homólogo/efeitos adversos , Adulto Jovem
3.
Nefrologia (Engl Ed) ; 40(3): 223-236, 2020.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-31901373

RESUMO

Patients with the dual burden of chronic kidney disease (CKD) and chronic congestive heart failure (HF) experience unacceptably high rates of symptom load, hospitalization, and mortality. Currently, concerted efforts to identify, prevent and treat HF in CKD patients are lacking at the institutional level, with emphasis still being placed on individual specialty views on this topic. The authors of this review paper endorse the need for a dedicated cardiorenal interdisciplinary team that includes nephrologists and renal nurses and jointly manages appropriate clinical interventions across the inpatient and outpatient settings. There is a critical need for guidelines and best clinical practice models from major cardiology and nephrology professional societies, as well as for research funding in both specialties to focus on the needs of future therapies for HF in CKD patients. The implementation of cross-specialty educational programs across all levels in cardiology and nephrology will help train future specialists and nurses who have the ability to diagnose, treat, and prevent HF in CKD patients in a precise, clinically effective, and cost-favorable manner.


Assuntos
Necessidades e Demandas de Serviços de Saúde , Insuficiência Cardíaca/epidemiologia , Insuficiência Renal Crônica/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Instituições de Assistência Ambulatorial/organização & administração , Biomarcadores , Cardiologia/educação , Fármacos Cardiovasculares/uso terapêutico , Terapia Combinada , Comorbidade , Currículo , Gerenciamento Clínico , Progressão da Doença , Diuréticos/uso terapêutico , Educação Médica , Educação em Enfermagem , Everolimo/efeitos adversos , Everolimo/uso terapêutico , Cardiopatias/diagnóstico , Cardiopatias/diagnóstico por imagem , Insuficiência Cardíaca/economia , Insuficiência Cardíaca/fisiopatologia , Insuficiência Cardíaca/terapia , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Incidência , Guias de Prática Clínica como Assunto , Prevalência , Prognóstico , Insuficiência Renal Crônica/economia , Insuficiência Renal Crônica/fisiopatologia , Insuficiência Renal Crônica/terapia , Terapia de Substituição Renal/efeitos adversos , Terapia de Substituição Renal/métodos , Pesquisa , Autocuidado
4.
Pharmacoecon Open ; 3(2): 229-235, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30324566

RESUMO

BACKGROUND: Philadelphia chromosome-negative (Ph-) relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukaemia (ALL) is rare, and information on its impact on healthcare systems is scarce. OBJECTIVE: To quantify the time and reimbursement associated with hospitalisations of patients with R/R ALL in a Spanish hospital. METHODS: Retrospective review of medical charts identified patients aged ≥ 18 years with Ph- R/R ALL hospitalised between 1998 and 2014. Data were collected from the date of first diagnosis of R/R ALL (index) until death or loss to follow-up. The primary endpoint was the proportion of time hospitalised during chemotherapy. Reimbursement associated with hospitalisations (including associated chemotherapy) was also assessed. RESULTS: Thirty-two patients were eligible for inclusion. Their median age was 41 years, and 50% had a first remission duration of ≤ 1 year; 34% had undergone allogeneic haematological stem-cell transplantation (alloHSCT). Overall, 31 patients had received intensive salvage chemotherapy, during which there were 42 hospitalisations (mean 1.4/patient; mean duration 26 days). Patients spent a mean of 71% of the chemotherapy period in hospital. Total mean reimbursement was €26,417 per patient, almost all (€25,723) attributable to inpatient stays (€18,986/hospitalisation). From the index date to death or loss to follow-up (excluding alloHSCT-related hospitalisations), there were 80 hospitalisations (mean duration 24 days); mean reimbursement was €16,692 per hospitalisation and €41,730 per patient. AlloHSCT (n = 8) involved 18 hospitalisations (mean reimbursement €39,782/hospitalisation; €89,510/patient). CONCLUSION: Data from this sample of patients suggest that hospitalisations in R/R ALL are lengthy and associated with high costs in Spain.

5.
Chemosphere ; 72(5): 826-35, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18377949

RESUMO

Elutriate embryo-larval bioassays with sea-urchins (Paracentrotus lividus) and ascidians (Ciona intestinalis) were conducted concurrently with trace metal analyses as part of an integrative assessment of sediment pollution at Ría de Pontevedra (Galicia, NW Spain). High metal contents in sediments were found in localised areas from the inner part of the estuary indicating a clear anthropogenic influence. In particular, very high Cu, Zn and Pb levels were found at sites P2 and P3, which were also the most toxic to the embryo-larval bioassays. Sediment quality guidelines were used to help in the ecological interpretation of sediment chemistry data and to identify pollutants of concern. Cu and Zn in P3 were consistently above the effects range median (ERM) values, which seem to be good predictors of toxicity to sea-urchin and ascidian embryos. A toxic unit approach, based on published EC(50) values and metal levels in elutriates, was used to assess the harmful ecological effects associated to sediment chemistry. Toxicity detected in P3 may be explained on the basis of the toxic unit model; however, the high toxicity detected at P2 may be attributable not only to the metals quantified in the analyses but also to unmeasured organic pollutants. Multidimensional scaling applied independently to the toxicology and chemistry data resulted in a good agreement between both types of configurations. Moreover, the Mantel test revealed a significant correlation (r(M)=0.481; p=0.019) between metal concentrations and toxicity data profiles, supporting the correspondence between configurations.


Assuntos
Sedimentos Geológicos/análise , Poluentes Químicos da Água/análise , Poluentes Químicos da Água/toxicidade , Poluição da Água/análise , Animais , Fenômenos Químicos , Físico-Química , Ciona intestinalis , Embrião não Mamífero/fisiologia , Crescimento/efeitos dos fármacos , Larva/crescimento & desenvolvimento , Larva/fisiologia , Metais/análise , Análise Multivariada , Padrões de Referência , Ouriços-do-Mar , Água do Mar/análise , Espanha
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA